Onyx Pharmaceuticals Inc. (NYSE: ONXX), a developer of cancer therapies, were up $2.40 to $51.75 in pre-open trading. ONXX released Q3 Nexavar sales of $105 million, beating Street expectations. Wachovia says, "With the ONXX/Bayer Nexavar joint venture touching profitability two quarters earlier than anticipated, we believe Street expectations for a Bayer acquisition of ONXX." ONXX has projected the next key clinical event will be in the 2nd half of 2008 for Phase 3 non-small cell lung cancer. ONXX over all option implied volatility of 58 is near its 26-week average of 55 according to Track Data, suggesting larger price risks.

[Update: ONXX shares were recently (12:05 p.m.) up $9.02, or 18.28% to $58.37.]

Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Option update: Onyx Pharma volatility elevated with rally originally appeared on BloggingStocks on Wed, 07 Nov 2007 12:06:00 EST. Please see our terms for use of feeds.